Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Table 3 Quality of life

Variable	Value
**Health-related QoL score (range 0–1)***
No RSV hospitalization	0.950
RSV hospitalization	0.880

From: Greenough A et al. [16], calculations based on Health Utility Index 2: Torrance GW et al. [17].
*QoL = Quality of Life

ISSN: 1824-7288